SLC2A1 and Sepsis: In sepsis, serum exosomes from patients with SIMD can target the transcription of glucose transporter GLUT1 (SLC2A1) in cardiomyocytes through miR-1262, inhibiting mitochondrial glycolysis rate and promoting cardiomyocyte apoptosis, ultimately aggravating myocardial injury (163).